DCP is intended for use as an aid in the risk assessment of patients with chronic liver disease for progression to hepatocellular carcinoma in conjuction with other laboratory findings, imaging studies and clinical assessment.
Immediately following collection, thoroughly mix sample by gently inverting 5 times
Frozen (strict) - 14 days
Refrigerated - NO
Ambient - NO
Liquid-phase binding assay (LiBaSys)
0.0 - 7.5 ng/mL